Trials in "pay for delay" antitrust cases—where branded and generic pharmaceutical companies stand accused of settling patent litigation claims in a way that unfairly props up drug prices—rarely go to trial. Given the dollar figures involved and the prospect of treble damages, the risks are high. That was especially true in a case that wrapped up recently against Gilead Sciences Inc. and Teva Pharmaceutical Industries Ltd. alleging the companies colluded to unfairly inflate the price for two key HIV drugs.